Lisata Therapeutics Inc (LSTA) Stock Price, Quote & News

Company Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens....

Industry: Biotechnology

Sector: Healthcare

Phone: 908 842 0100

Website: www.lisata.com

Address:

110 Allen Road, 2nd Floor, Basking Ridge, United States

Mike22332233 May. 10 at 2:46 AM

$SLS is by far my top holding, with that position consisting in about a 33% equal weight in its common stock and in '27 Leaps and in '28 Leaps .... my other post had the first 5 of my top 10 holdings …. and here is the second half of that list: ,,,,$ATER, $LSTA, $VNDA and $INBX ... FOLLOW my posts to see all DD and my expected returns on these very special situations ... YOU might like what you see !!!

0 · Reply

Mike22332233 May. 10 at 12:37 AM

$LSTA $LSTA stock price has plummeted because the BO at $5.00 was delayed and thought to be over .... Now, I think that the deal will indeed go through by the end of the month FOR A HUGE RETURN !!! ... In addition to the $5.00 BO payout, each share will get a CVR with a potential $1.00 eventual payout .... If you FOLLOW my posts, you know I always look for special situations with very healthy upside !!!!

1 · Reply

ProWinners May. 8 at 6:11 PM

$LSTA Veey bullish setup

0 · Reply

KP2021 May. 8 at 3:09 PM

$LSTA 🤔

0 · Reply

OfficialStocktwitsUser May. 7 at 11:23 PM

$LSTA RSI: 50.00, MACD: -0.3470 Vol: 0.62, MA20: 3.50, MA50: 4.31 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

AlphaOutlaw May. 5 at 4:02 AM

$LSTA

0 · Reply

Tom__Brady May. 4 at 10:25 PM

$LSTA as horrible as the deal is for shareholders, just want it to be done at this point and move on

0 · Reply

TwongStocks May. 4 at 2:48 PM

$LSTA Kuva issued a PR saying that they intend to commence the tender offer by May 29 https://www.einnews.com/pr_news/910236854/kuva-intends-to-commence-tender-offer-for-lisata-therapeutics-by-may-29-2026 Kuva intends to commence the Offer to acquire Lisata on or before May 29, 2026, on the terms set forth in the Merger Agreement. Pursuant to the Amendment and Waiver, Kuva has agreed to cover certain of Lisata’s operating expenses until the Offer is commenced. “We remain committed to completing this transaction,” said Mark Land, Chief Executive Officer of Kuva.

1 · Reply

DesseinH May. 4 at 1:25 PM

$LSTA I just read that again, seems like we are in for some choppy weather tbh. not liking all these delays at all

0 · Reply

TwongStocks May. 4 at 1:08 PM

$LSTA Link to the waiver agreement https://www.sec.gov/Archives/edgar/data/320017/000114036126018651/ef20072320_ex2-1.htm • Waiver period lasts until May 29. During the waiver period, LSTA agreed not to pursue any claims against Kuva. • Kuva must make certain payments to LSTA (screenshots). They can stop making these payments if the tender offer commences. If Kuva waits until May 29 to initiate the tender, the combined payments to LSTA will total $1.1M. If Kuva misses a payment, LSTA can terminate the waiver and pursue claims against Kuva. • Kuva must initiate the tender offer by the end of the waiver period (May 29).

0 · Reply

Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders

SILA

2026-03-06T23:25:14.000Z - 2 months ago

Lisata Therapeutics to be acquired by Kuva Labs for $5 per share cash plus CVR

Mar 6, 2026, 6:15 PM EST - 2 months ago

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

2026-01-27T13:05:23.000Z - 3 months ago

Lisata Therapeutics announces mutual termination of license agreement with Qilu

Jan 27, 2026, 8:00 AM EST - 3 months ago

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

2026-01-21T14:35:15.000Z - 4 months ago

Lisata Therapeutics downgraded to Hold from Buy at Brookline

2026-01-21T12:05:32.000Z - 4 months ago

Lisata Therapeutics to be acquired by Kuva Labs for $4.00 per share

Jan 21, 2026, 7:00 AM EST - 4 months ago

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Nov 6, 2025, 4:30 PM EST - 6 months ago

Lisata Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:05 PM EST - 6 months ago

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 8:00 AM EST - 6 months ago

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year'

2025-11-04T22:30:47.000Z - 6 months ago

Lisata Therapeutics highlights iRGD cyclic peptide product candidate data

Nov 4, 2025, 4:00 PM EST - 6 months ago

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

Oct 30, 2025, 8:00 AM EDT - 6 months ago

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

Oct 20, 2025, 1:30 PM EDT - 7 months ago

Lisata Therapeutics Transcript: LD Micro Main Event XIX Investor Conference

Oct 13, 2025, 8:00 AM EDT - 7 months ago

Lisata Therapeutics to Present at LD Micro Main Event XIX

2025-10-08T12:36:18.000Z - 7 months ago

Lisata Therapeutics, Catalent announce global ADC licensing agreement

Oct 8, 2025, 8:30 AM EDT - 7 months ago

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

2025-09-29T12:11:11.000Z - 8 months ago

Lisata Therapeutics announces results from pancreatic cancer cohort of CENDIFOX

Sep 29, 2025, 8:00 AM EDT - 8 months ago

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Lisata Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 9 months ago

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 AM EDT - 10 months ago

Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025

2025-07-17T12:10:54.000Z - 10 months ago

Lisata Therapeutics, WARPNINE announce iLSTA trial enrollment completion

2025-07-17T12:10:41.000Z - 10 months ago

Lisata Therapeutics announces preliminary data from iLSTA trial

Jul 17, 2025, 8:00 AM EDT - 10 months ago

Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update

2025-07-15T15:20:12.000Z - 10 months ago

Lisata Therapeutics price target raised to $32 from $20 at Brookline

Jul 15, 2025, 8:00 AM EDT - 10 months ago

Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide

2025-06-26T12:11:21.000Z - 11 months ago

Lisata Therapeutics announces preliminary cohort B results from ASCEND trial

2025-06-17T12:16:04.000Z - 11 months ago

Lisata, GATC announces strategic alliance to advance AI-driven drug discovery

Jun 17, 2025, 8:00 AM EDT - 11 months ago

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

Jun 11, 2025, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Present at the 2025 BIO International Convention

May 8, 2025, 4:30 PM EDT - 1 year ago

Lisata Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:00 AM EDT - 1 year ago

Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025

2025-04-15T12:11:26.000Z - 1 year ago

Lisata Therapeutics announces research license with Catalent

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces Research License with Catalent

Mar 6, 2025, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Present at the Investival Showcase USA

2025-03-05T13:42:39.000Z - 1 year ago

Lisata Therapeutics, GATC Health consummate first step in collaboration

Mar 5, 2025, 8:30 AM EST - 1 year ago

Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

2025-02-27T22:10:29.000Z - 1 year ago

Lisata Therapeutics exploring certepetide’s versatility in non-cancerous setting

Feb 27, 2025, 4:30 PM EST - 1 year ago

Lisata Therapeutics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Feb 20, 2025, 8:00 AM EST - 1 year ago

Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025

2025-01-23T13:05:26.000Z - 1 year ago

Lisata, WARPNINE announces preliminary results from Phase 1b/2 iLSTA trial

2025-01-22T13:21:05.000Z - 1 year ago

Lisata Therapeutics reports preliminary Cohort A data from Phase 2 ASCEND trial

Jan 15, 2025, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

2024-12-10T13:40:32.000Z - 1 year ago

Lisata Therapeutics complete enrollment in CENDIFOX trial

Dec 10, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

Nov 19, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year'

Nov 12, 2024, 4:30 PM EST - 1 year ago

Lisata Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 9:23 AM EST - 1 year ago

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

Nov 6, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

Oct 29, 2024, 2:00 PM EDT - 1 year ago

Lisata Therapeutics Transcript: LD Micro Main Event XVI

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

Aug 12, 2024, 4:30 PM EDT - 1 year ago

Lisata Therapeutics Earnings Call Transcript: Q2 2024

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

Jul 16, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Jul 10, 2024, 8:00 AM EDT - 2 years ago

Lisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

Jun 13, 2024, 8:30 AM EDT - 2 years ago

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

May 28, 2024, 8:30 AM EDT - 2 years ago

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

May 20, 2024, 8:30 AM EDT - 2 years ago

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

May 9, 2024, 4:30 PM EDT - 2 years ago

Lisata Therapeutics Earnings Call Transcript: Q1 2024

May 9, 2024, 4:05 PM EDT - 2 years ago

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 8:00 AM EDT - 2 years ago

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

Apr 23, 2024, 7:30 AM EDT - 2 years ago

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Apr 9, 2024, 10:00 AM EDT - 2 years ago

Lisata Therapeutics Transcript: LD Micro Invitational XIV 2024

Apr 9, 2024, 8:30 AM EDT - 2 years ago

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Apr 3, 2024, 8:30 AM EDT - 2 years ago

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Feb 29, 2024, 4:30 PM EST - 2 years ago

Lisata Therapeutics Earnings Call Transcript: Q4 2023

Feb 29, 2024, 4:05 PM EST - 2 years ago

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mike22332233 May. 10 at 2:46 AM

0 · Reply

Mike22332233 May. 10 at 12:37 AM

1 · Reply

ProWinners May. 8 at 6:11 PM

$LSTA Veey bullish setup

0 · Reply

KP2021 May. 8 at 3:09 PM

$LSTA 🤔

0 · Reply

OfficialStocktwitsUser May. 7 at 11:23 PM

0 · Reply

AlphaOutlaw May. 5 at 4:02 AM

$LSTA

0 · Reply

Tom__Brady May. 4 at 10:25 PM

$LSTA as horrible as the deal is for shareholders, just want it to be done at this point and move on

0 · Reply

TwongStocks May. 4 at 2:48 PM

1 · Reply

DesseinH May. 4 at 1:25 PM

$LSTA I just read that again, seems like we are in for some choppy weather tbh. not liking all these delays at all

0 · Reply

TwongStocks May. 4 at 1:08 PM

0 · Reply

DesseinH May. 4 at 12:31 PM

$LSTA This is basically free money. Kuva are obligated to meet the tender offer, given they will be liable should they fail to do so, wonder why it is not trading at 5$ to be honest

0 · Reply

focafoca99 May. 4 at 11:20 AM

$LSTA extended the tender offer deadline to May 29, 2026 via an amendment and waiver to its merger agreement.

0 · Reply

TwongStocks May. 4 at 11:03 AM

$LSTA New SEC filing. Kuva and LSTA agreed to extend the deadline for Kuva to commence the tender offer. New deadline is May 29. https://www.sec.gov/ix?doc=/Archives/edgar/data/0000320017/000114036126018651/ef20072320_form8k.htm

0 · Reply

TwongStocks Apr. 28 at 12:19 PM

$LSTA Wonder how much more time they'll give Kuva to sort out the financing issues.

1 · Reply

PyraWeb Apr. 26 at 5:44 PM

$LSTA we are witnessing some very very odd price action here. After many years of negative pa, it finally popped, not nearly enough, but the boulder is rolling per se. And they want to sell at the bottom…David ‘Doesn’t release fluff’ Mazzo staying very quiet when he needs to be selling his company. No one is satisfied selling to MI2 holding(Kuva), a co once advertised as Basking Ridge based(until it was removed from the site). That tells me LSTA hasn’t put a fair effort for investors to find a reasonable offer,why? Support found on side cap lvl 3.00, bullish harami. Time for real news now or I doubt this is sustainable, being that Kuva can’t afford the buyout…they should pay 2 million to LSTA now. With that $$$, Mazzo and Buck should get off their behinds and find a decent offer in line with Wall Street price predictions. And one in line with a complete response in their study. Menditto should write investors back. It’s not a hard concept. Or it’s one nice grift for them all. 🌈🕸📐

0 · Reply

KP2021 Apr. 23 at 8:47 AM

$LSTA what do they know that we don’t?

1 · Reply

FlippinLinknz Apr. 22 at 6:11 AM

$LSTA 👀

0 · Reply

topstockalerts Apr. 21 at 4:52 PM

$LSTA new high of day 🙌

0 · Reply

prismmarketview Apr. 21 at 4:24 PM

PRISM Mid-Day Movers: Aerospace & Defense and Pharmaceuticals are Today’s Leaders. Velo3D, Inc ( NASDAQ: $VELO) ripping +33% to ~$15.59 on heavy volume after debt cut (~60%), CEO debt-to-equity move, and growing defense backlog ($9.8M contract). Sees $60–$70M 2026 rev + positive EBITDA H2. SciSparc Ltd. (NASDAQ: $SPRC) up ~23% to ~$4.23 as restructuring + pivot (MUSE IP, AI drug discovery) fuels speculative momentum in thin float. Other Notable Movers: Lisata Therapeutics ( $LSTA) up 16% Firefly Neuroscience. ( $AIFF) up 14% HUB Security ( $HUBC)down -51% https://prismmarketview.com/prism-mid-day-movers-aerospace-defense-and-pharmaceuticals-are-todays-leaders/

0 · Reply

prismmarketview Apr. 21 at 4:23 PM

PRISM Mid-Day Movers: Aerospace & Defense and Pharmaceuticals are Today’s Leaders. Velo3D, Inc ( NASDAQ: $VELO) ripping +33% to ~$15.59 on heavy volume after debt cut (~60%), CEO debt-to-equity move, and growing defense backlog ($9.8M contract). Sees $60–$70M 2026 rev + positive EBITDA H2. SciSparc Ltd. (NASDAQ: $SPRC) up ~23% to ~$4.23 as restructuring + pivot (MUSE IP, AI drug discovery) fuels speculative momentum in thin float. Other Notable Movers: Lisata Therapeutics ( $LSTA) up 16% Firefly Neuroscience. ( $AIFF) up 14% HUB Security (NASDAQ: $HUBC)down -51% https://prismmarketview.com/prism-mid-day-movers-aerospace-defense-and-pharmaceuticals-are-todays-leaders/

0 · Reply

KP2021 Apr. 21 at 4:03 PM

$LSTA looks like news incoming

1 · Reply

RichMitch Apr. 20 at 9:27 PM

$AMS $MYSE $BZAI $PHGE $LSTA Hmmm 🤔

0 · Reply

Market Cap	29.69M
Revenue (ttm)	170,000.00
Net Income (ttm)	-16.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-9,758.82%
Debt to Equity Ratio	0.00

Volume	18,000
Avg Vol	79,152
Day's Range	N/A - N/A
Shares Out	9.11M
Stochastic %K	53%
Beta	0.81
Analysts	Sell
Price Target	$9.50